VOR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Telitacicept demonstrates deep and durable symptom reduction through 48 weeks in generalized myasthenia gravisSep 29, 2026
- Telitacicept received NMPA approval in China for Sjögren's diseaseJun 8, 2026
- Vor Bio dosed the first patient in its global Phase 3 UPSTREAM trial of Telitacicept in Sjögren's diseaseMar 30, 2026
- Vor Bio to host webcast on late-breaking China Phase 3 Telitacicept data in primary Sjögren's diseaseOct 23, 2025
- Vor Bio announces late-breaking poster presentation of Phase 3 primary Sjögren's disease clinical study at ACR Convergence 2025Sep 29, 2025